Stem cell properties in cell cultures from different stage of melanoma progression

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 3, 2014, Pages 171-181

  Magnoni, Cristina ^a   Giudice, Stefania ^a   Pellacani, Giovanni ^a   Bertazzoni, Giorgia ^a   Longo, Caterina ^b   Veratti, Eugenia ^a   Morini, Daria ^a   Benassi, Luisa ^a   Vaschieri, Cristina ^a   Azzoni, Paola ^a   De Pol, Anto ^a   Seidenari, Stefania ^a   Tomasi, Aldo ^a   Pollio, Annamaria ^c   Ponti, Giovanniv ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

CD133; CD166; CD20; Malignant melanoma; Melanoma cell cultures; Mesenchymal stem cell antigens; Nestin; S100

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALKALINE PHOSPHATASE; CD133 ANTIGEN; CD146 ANTIGEN; CD20 ANTIGEN; ENDOGLIN; NESTIN; THY 1 ANTIGEN; DIFFERENTIATION ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL RENEWAL; CFU COUNTING; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT LENTIGO; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; SKIN BIOPSY; TUMOR VOLUME; VERY ELDERLY; ADIPOGENESIS; ANTIGENIC VARIATION; BONE DEVELOPMENT; CANCER STAGING; CARCINOGENESIS; CELL LINEAGE; CELL SEPARATION; CULTURE TECHNIQUE; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR;

ADIPOGENESIS; ANTIGENIC VARIATION; ANTIGENS, DIFFERENTIATION; CARCINOGENESIS; CELL CULTURE TECHNIQUES; CELL LINEAGE; CELL SEPARATION; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; NESTIN; OSTEOGENESIS; SKIN NEOPLASMS; TUMOR STEM CELL ASSAY;

EID: 84910128795     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31828ff701     Document Type: Article

References (38)

1. Demierre MF, Nathanson L. Chemoprevention of melanoma: An unexplored strategy. J Clin Oncol. 2003;21:158-165.
2. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J. 2010;16:399-403.
3. Ugurel S, Utikal J, Becker JC. Tumor biomarkers in melanoma. Cancer Control. 2009;16:219-224.
4. Strauss R, Li ZY, Liu Y, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011;6:e16186.
5. Mikesh LM, Kumar M, Erdag G, et al. Evaluation of molecular markers of mesenchymal phenotype in melanoma. Melanoma Res. 2010;20:485-495.
6. Turley EA, Veiseh M, Radisky DC, et al. Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol. 2008;5:280-290.
7. Kopelovich L. Genetic predisposition to cancer in man: in vitro studies. Int Rev Cytol. 1982;77:63-88.
8. Winnepenninckx V, De Vos R, Stas M, et al. New phenotypical and ultrastructural findings in spindle cell (desmoplastic/neurotropic) melanoma. Appl Immunohistochem Mol Morphol. 2003;11:319-325.
9. Lehmann JM, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA. 1989;86:9891-9895.
10. Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood. 2003;102:184-191.
11. Bu P, Zhuang J, Feng J, et al. Anti-CD146 monoclonal antibody AA98 inhibits angiogenesis via suppression of nuclear factor-kappa B activation. Mol Cancer Ther. 2006;5:2872-2878.
12. Kang Y, Wang F, Feng J, et al. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res. 2006;16:313-318.
13. Zheng C, Qiu Y, Zeng Q, et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: The role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol. 2009;41:2163-2172.
14. Covas DT, Panepucci RA, Fontes AM, et al. Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and gene-expression profile with CD146+ perivascular cells and fibroblasts. Exp Hematol. 2008;36:642-654.
15. Eng W, Tschen JA. Comparison of S-100 versus hematoxylin and eosin staining for evaluating dermal invasion and peripheral margins by desmoplastic malignant melanoma. Am J Dermatopathol. 2000;22:26-29.
16. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell. 1975;6:331-344.
17. Mitchell JB, McIntosh K, Zvonic S, et al. Immunophenotype of human adipose-derived cells: Temporal changes in stromal-associated and stem cell-associated markers. Stem Cells. 2006;24:376-385.
18. Friedenstein AY. Induction of bone tissue by transitional epithelium. Clin Orthop Relat Res. 1968;59:21-37.
19. Lillie RD, Ashburn LL. Supersaturated solutions of fat stains in dilute isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer's technique. Arch Pathol. 1943;36:432-440.
20. Gregory CA, Gunn WG, Peister A, et al. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem. 2004;329:77-84.
21. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317.
22. Sharma BK, Manglik V, Elias EG. Immuno-expression of human melanoma stem cell markers in tissues at different stages of the disease. J Surg Res. 2010;163:e11-e15.
23. Liu F, Gomez Garcia AM, Meyskens FL Jr. NADPH oxidase 1 overexpression enhances invasion via matrix metalloproteinase-2 and epithelial-mesenchymal transition in melanoma cells. J Invest Dermatol. 2012;132:2033-2041.
24. Zeng Q, Li W, Lu D, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA. 2012;109:1127-1132.
25. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
26. Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007;20:102-107.
27. Grichnik JM. Genomic instability and tumor stem cells. J Invest Dermatol. 2006;126:1214-1216.
28. Piras F, Perra MT, Murtas D, et al. The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep. 2010;23:17-24.
29. Pan C, Kumar C, Bohl S, et al. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell typespecific functions. Mol Cell Proteomics. 2009;8:443-450.
30. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005; 65:9328-9337.
31. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320-4333.
32. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: A first step toward manageable disease. Clin Cancer Res. 2011;17:1658-1663.
33. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer. 2012;12:349-361.
34. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;24:235-242.
35. Pinc A, Somasundaram R, Wagner C, et al. Targeting CD20 in melanoma patients at high risk of disease recurrence. Mol Ther. 2012;20:1056-1062.
36. Schlaak M, Schmidt P, Bangard C, et al. Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 2012;3:22-30.
37. Forte G, Sorrentino R, Montinaro A, et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol. 2012;189:2226-2233.
38. Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71:2892-2900.